A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma

Preclinical and phase I clinical data suggest that 9-nitrocamptothecin (9NC) is an agent with potential anticancer activity. A phase II study was undertaken in order to evaluate the potential benefit of oral 9NC administration in patients with advanced pancreatic cancer. This was the first clinical...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2001-11, Vol.48 (5), p.417-420
Hauptverfasser:	KONSTADOULAKIS, Manousos M, ANTONAKIS, Pantelis T, TSIBLOULIS, Basil G, STATHOPOULOS, George P, MANOURAS, Andreas P, MYLONAKI, Despoina B, GOLEMATIS, Basil X
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adult Aged Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Camptothecin - analogs & derivatives Camptothecin - therapeutic use Chemotherapy Female Humans Male Medical sciences Middle Aged Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pharmacology. Drug treatments Prospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!